| Title | Role of Pemetrexed and Platinums Combination in Patients with Non-Small Cell Lung Cancer. | | Author(s) | Chen M, Shao W, He J, Wang D | | Institution | Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College; Research Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease. No. 151, Yanjiang Rd, Guangzhou 510120, Guangdong Province, PR China. drjianxing.he@gmail.com. | | Source | Curr Drug Targets 2009 Sep 19. | | Abstract | The incidence of lung cancer in 2007 is estimated to be 213,380 with 160,390 deaths in the United States. It will contribute to 31% of male and 26% of female cancer-related deaths and is the largest cause of cancer-related mortality in both men and women. Despite some advances in the treatment of advanced non-small cell lung cancer (NSCLC), the introduction of third-generation cytotoxic agents (vinorelbine, gemcitabine, docetaxel, irinotecan, and paclitaxel) has not achieved a breakthrough in the dismal prognosis of this disease. Several meta-analyses have proved the superiority of 2-drug chemotherapy and cisplatin-based chemotherapy, but no gold standard exists. This paper summarizes the clinical data of a new cytotoxic agent, pemetrexed, and its combination with platinums in the treatment of NSCLC. The addition of the vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) or an EGFR-targeted drug (cetuximab) to pemetrexed/platinum in NSCLC, and the role of pemetrexed/platinum in adjuvant chemotherapy for early-stage NSCLC were also discussed in this paper. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19839930 |
|
